Pfizer Working To Resolve Sickle Cell Drug Hold Up, Dolsten Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Rivipansel, partnered with GlycoMimetics, is one of the most advanced drugs in Pfizer’s rare disease pipeline. Phase III studies have been delayed, however, due to a manufacturing issue impacting supply.